Biologic Approaches to Treat Substance-Use Disorders

Area of Science:

• Pharmacology
• Neuroscience
• Addiction Medicine

Background:

• Traditional treatments for substance-use disorders (SUDs) primarily use pharmacodynamic strategies.
• Biologics represent a novel therapeutic class for SUDs, employing pharmacokinetic principles.
• These biologics aim to reduce or eliminate abused drugs from reaching the central nervous system (CNS).

Purpose of the Study:

• To evaluate the efficacy of biologics in treating substance-use disorders.
• To explore the pharmacokinetic approach of biologics in managing addiction.
• To review preclinical and clinical findings on biologics for SUDs.

Main Methods:

• Review of preclinical studies on biologics for various substance-use disorders.
• Analysis of emerging clinical trial data for first-generation biologic therapies.
• Assessment of the pharmacokinetic principle underlying biologic action in the CNS.

Main Results:

• Preclinical data suggest biologics can facilitate abstinence and prevent relapse for substances like nicotine, heroin, cocaine, and methamphetamine.
• Clinical trial results for biologics in treating SUDs are currently mixed.
• First-generation biologic tools have yielded valuable insights despite varied outcomes.

Conclusions:

• Biologics present a promising pharmacokinetic strategy for treating substance-use disorders.
• Further development of biologic therapies is warranted, informed by current clinical insights.
• Biologics may offer effective and commercially viable treatments for tobacco, cocaine, and methamphetamine use disorders.